Expands ICON's leadership in Health Outcomes Research and Commercialisation Services
A global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has acquired the Mapi Group, a leading Patient-Centered Health Outcomes Research and Commercialisation company, currently based in the Translation & Innovation Hub (I-HUB).
Article text (excluding photos or graphics) available under an Attribution-NonCommercial-ShareAlike Creative Commons license.
Photos and graphics subject to third party copyright used with permission or © Imperial College London.
Reporter
Katrina McClellan
Investment Office
